<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040075</url>
  </required_header>
  <id_info>
    <org_study_id>184 Resistance Study</org_study_id>
    <nct_id>NCT04040075</nct_id>
  </id_info>
  <brief_title>Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy</brief_title>
  <official_title>Open-label Switch Study From a Regimen of Elvitegravir/Tenofovir Alafenamide/Emtricitabine/Cobicistat and Darunavir, to a FDC of Bictegravir/Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed HIV-l Subjects Known to Have an 184 V/I Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southampton Healthcare, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southampton Healthcare, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label Study to Evaluate Switching from a Regimen of Elvitegravir/Tenofovir
      alafenamide/Emtricitabine/Cobicistat and Darunavir, to a Fixed-Dose Combination of
      Bictegravir/Tenofovir alafenamide/Emtricitabine in Virologically Suppressed HIV-1 Subjects
      who are known to have a I84 V/I Mutation
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>subjects under current treatment for HIV with the I84 I/V Mutation Resistance</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Test the safety and effectiveness of the drug Biktarvy in subjects known to have the 184 V/I resistance mutation.</measure>
    <time_frame>In 48 week study</time_frame>
    <description>Pure Virologic Response (PVR) with HIV-1 RNA &lt; 50 copies/mL at week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Test the safety and effectiveness of the drug Biktarvy in subjects known to have the 184 V/I resistance mutation.</measure>
    <time_frame>In 48 Week study</time_frame>
    <description>Pure Virologic Response (PVR) with HIV-1 RNA &lt; 50 copies/mL at week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test the safety and effectiveness of the drug Biktarvy in subjects known to have the 184</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Pure Virologic Response (PVR) with HIV-1 RNA &lt; 50 copies/mL at week 48</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open label Biktarvy to establish suppression of HIV 1 with 184 V/I Resistance Mutation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biktarvy Tab</intervention_name>
    <description>Antiretroviral drug</description>
    <arm_group_label>Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The ability to understand and sign a written informed consent which must be obtained
             prior to initiation of study procedures.

          -  Age equal to or greater than 18 years.

          -  Currently receiving an ARV regimen of EVG/F/TAF +DRV greater than six month.

          -  Documented plasma HIV - 1 RNA less than 50 copies/ml during the treatment with
             Elvitegravir/F/TAF for a minimum of 12 months prior to screening, on two separate
             determinations, with one determination within 3 months prior to screening.

          -  Have a documented 184 V/I resistant mutation.

          -  HIV-1 RNA levels &lt; 50 copies per ml at screening.

          -  Estimated GFR &gt;than or equal to 30 mls/min.

          -  AST and ALT equal to or less than 5 times upper limit of normal.

          -  Total bilirubin less than or equal to 1.5 mg/dl or normal direct bilirubin.

          -  Adequate hematologic function (absolute neutrophil count equal to or greater than
             750/mm to the third, platelets equal to or greater than 50,000/mm to the third,
             Hemoglobin equal to or greater than 8.5 g/dl).

          -  Persons of child bearing potential must have negative serum pregnancy test at
             screening.

          -  Male participants and persons of child bearing potential who engage in heterosexual
             intercourse must agree to use our protocol specified methods of contraception.

          -  Female participants must agree to refrain from egg donation from first dose of FDC of
             B/F/TAF and throughout the study.

          -  Male participants must agree to refrain from sperm donation from first dose until at
             least 30 days after last dose of drug.

          -  Life expectancy equal to or greater than one year.

        Exclusion Criteria:

          -  No desire to switch from current antiretroviral treatment.

          -  Any previous use of B/F/TAF.

          -  Any opportunistic illness indicative of stage 3 HIV diagnosed within 30 days prior to
             screening.

          -  Malignancy within 5 years of screening other than cutaneous Kaposi's sarcoma,
             completed resected non melanoma skin cancer, basal cell carcinoma, or noninvasive
             cutaneous squamous carcinoma, or completed resected carcinoma in situ of the cervix or
             anus. A prior malignancy treated with curative therapy and for which there has been no
             evidence of disease for at least 5 years prior to screening.

          -  Known hypersensitivity to FDC of B/F/TAF tablets their metabolites or formulation.

          -  No active treatment of Hepatitis C during the 48 weeks of the study.

          -  Females who are pregnant confirmed by serum pregnancy test.

          -  Females who are breast feeding.

          -  Suspected Biktarvy resistance mutations, except 184 V/I.

          -  Patients who need to take Dofetilide, Rifampin, Rifapentine, Rifabutin, phenobarbital,
             phenytoin, carbamazepine, oxcarbazepine, and antiretrovirals not part of the study and
             St. John's Wart during.

          -  Acute Hepatitis in the 30 days prior to screening.

          -  Active tuberculosis infection.

          -  Current alcohol or substance use judged by the investigator to potentially interfere
             with subject study compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southampton Healthcare, Inc.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelle Thompson, CRC</last_name>
      <phone>314-647-2200</phone>
      <phone_ext>116</phone_ext>
      <email>kthompson@shcstl.com</email>
    </contact>
    <contact_backup>
      <last_name>Cindy Tobias, R.N.</last_name>
      <phone>1-314-647-2200</phone>
      <phone_ext>114</phone_ext>
      <email>ctobias@shcstl.com</email>
    </contact_backup>
    <investigator>
      <last_name>David J Prelutsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tassy N Hayden, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sam T Tochtrop, D.O.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

